Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Regulatory Filings Classification · 96% confidence The document is a mandatory monthly return (Form FF301) filed with the Hong Kong Stock Exchange under Listing Rule Chapter 19B, detailing movements in issued shares, treasury shares, public float confirmation, and share option scheme balances. It does not present financial results or strategic commentary, nor is it an annual or interim report; rather it is a routine regulatory compliance filing. Hence it best fits the catch-all category for general regulatory announcements (RNS).
2026-06-01 English
INSIDE INFORMATION REGISTRATION OF MEDIUM TERM NOTES BY THE NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS
Capital/Financing Update Classification · 90% confidence The document is a formal announcement under the HKEX Listing Rules regarding a proposed issuance of medium term notes (debt financing) up to RMB5 billion. It is not a financial report or interim results, nor a share or director dealing report. It clearly relates to fundraising/financing activities (debt issuance), which falls under Capital/Financing Update (CAP).
2026-05-29 English
FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED)
Notice of Dividend Amount Classification · 100% confidence The document is an announcement titled 'FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED)' from China Resources Pharmaceutical Group Limited. It provides detailed information about the dividend amount, currency options, dates related to dividend approval, ex-dividend date, record date, payment date, and other related administrative details. The document is relatively short (3952 characters) and focuses solely on dividend declaration and related logistics. It does not contain financial statements, management discussion, or other report content. Therefore, it fits the category of a Notice of Dividend Amount (DIV).
2026-05-19 English
Proxy Form
AGM Information Classification · 95% confidence The document is a proxy form for use at the Annual General Meeting (AGM) of China Resources Pharmaceutical Group Limited. It includes instructions for shareholders to appoint proxies and vote on resolutions such as receiving the audited financial statements, declaring dividends, re-electing directors, appointing auditors, and authorizing share buybacks and issuances. The document is not the actual AGM report or financial statements but a form facilitating shareholder voting at the AGM. Therefore, it is classified as AGM Information (AGM-R). The document length is 6642 characters, which is consistent with a detailed proxy form rather than a brief announcement or a full report.
2026-05-19 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is a notice of an Annual General Meeting (AGM) for China Resources Pharmaceutical Group Limited. It includes details about the meeting date, agenda items such as receiving audited financial statements, re-election of directors, dividend declaration, and authorizations for share buy-back and allotment. The document does not contain the actual financial statements or detailed reports but serves as an announcement for the AGM and the matters to be discussed and voted on. It is not a full annual report, audit report, or financial statement. Therefore, it fits the category of AGM Information, which includes presentations and materials shared during the AGM or notices about the AGM.
2026-05-19 English
PROPOSALS FOR GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES, RE-ELECTION OF RETIRING DIRECTORS, APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is a circular from China Resources Pharmaceutical Group Limited dated 19 May 2026, addressing shareholders about the upcoming Annual General Meeting (AGM) scheduled for 12 June 2026. It includes proposals for general mandates to buy back shares and to issue shares, re-election of retiring directors, appointment of auditor, and the notice of the AGM itself. The document contains detailed information about the AGM agenda, including resolutions to be proposed and explanatory statements, as well as the notice of the meeting on pages 19 to 23. It is not a financial report, earnings release, or audit report, but rather a comprehensive circular related to the AGM. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length (15,000 characters) and content confirm it is the circular for the AGM, not just an announcement or proxy solicitation. Therefore, the appropriate classification is AGM-R with high confidence.
2026-05-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.